Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 204, Issue 10, Pages 2363-2372Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20071053
Keywords
-
Categories
Funding
- Multiple Sclerosis Society [560, 780, 836, 837] Funding Source: Medline
Ask authors/readers for more resources
Axonal injury is considered the major cause of disability in patients with multiple sclerosis ( MS), but the underlying effector mechanisms are poorly understood. Starting with a proteomics- based approach, we identified neurofascin- specific autoantibodies in patients with MS. These autoantibodies recognize the native form of the extracellular domains of both neurofascin 186 ( NF186), a neuronal protein concentrated in myelinated fibers at nodes of Ranvier, and NF155, the oligodendrocyte- specific isoform of neurofascin. Our in vitro studies with hippocampal slice cultures indicate that neurofascin antibodies inhibit axonal conduction in a complement- dependent manner. To evaluate whether circulating antineurofascin antibodies mediate a pathogenic effect in vivo, we cotransferred these antibodies with myelin oligodendrocyte glycoprotein - specific encephalitogenic T cells to mimic the inflammatory pathology of MS and breach the blood - brain barrier. In this animal model, antibodies to neurofascin selectively targeted nodes of Ranvier, resulting in deposition of complement, axonal injury, and disease exacerbation. Collectively, these results identify a novel mechanism of immune- mediated axonal injury that can contribute to axonal pathology in MS.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available